Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease

Not Recruiting

Trial ID: NCT00186667

Age - 18 Years-70 Years Condition - Blood and Marrow Transplant (BMT) Gender - All Accepting Healthy Volunteers - No

Purpose

Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.

Official Title

An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant

Stanford Investigator(s)

Laura Johnston
Laura Johnston

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Eligibility


Inclusion Criteria:- active chronic GvHD

   - ANC > 1000/mm^3

   - therapeutic cyclosporine Exclusion Criteria:- uncontrolled systemic infection

   - elevated serum creatinine

View More
View Less

Intervention(s):

procedure: high dose chemotherapy and autologous hematopoietic cell transplant

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822

New Trial Alerts

©2024 Stanford Medicine